WO1999009965A3 - Anti-inflammatory agent - Google Patents
Anti-inflammatory agent Download PDFInfo
- Publication number
- WO1999009965A3 WO1999009965A3 PCT/JP1998/003692 JP9803692W WO9909965A3 WO 1999009965 A3 WO1999009965 A3 WO 1999009965A3 JP 9803692 W JP9803692 W JP 9803692W WO 9909965 A3 WO9909965 A3 WO 9909965A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- group
- inflammatory agent
- formula
- ring
- Prior art date
Links
- 229940121363 anti-inflammatory agent Drugs 0.000 title abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002300813A CA2300813A1 (en) | 1997-08-21 | 1998-08-20 | Anti-inflammatory agent |
EP98938913A EP1007038A2 (en) | 1997-08-21 | 1998-08-20 | Anti-inflammatory agent |
AU87479/98A AU8747998A (en) | 1997-08-21 | 1998-08-20 | Anti-inflammatory agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/225302 | 1997-08-21 | ||
JP22530297 | 1997-08-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999009965A2 WO1999009965A2 (en) | 1999-03-04 |
WO1999009965A3 true WO1999009965A3 (en) | 1999-05-20 |
Family
ID=16827222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/003692 WO1999009965A2 (en) | 1997-08-21 | 1998-08-20 | Anti-inflammatory agent |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1007038A2 (en) |
AU (1) | AU8747998A (en) |
CA (1) | CA2300813A1 (en) |
WO (1) | WO1999009965A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7364736B2 (en) | 2001-06-26 | 2008-04-29 | Amgen Inc. | Antibodies to OPGL |
US8950405B2 (en) | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
US9060843B2 (en) | 2005-07-18 | 2015-06-23 | Tearscience, Inc. | Method and apparatus for treating gland dysfunction employing heated medium |
US9314369B2 (en) | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003508391A (en) | 1999-08-31 | 2003-03-04 | マキシア・ファーマシューティカルズ・インコーポレイテッド | Benzylidene-thiazolidinediones and analogs and their use in treating diabetes |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
US20030060488A1 (en) * | 2000-02-10 | 2003-03-27 | Yasuo Sugiyama | Drug comprising combination |
AU2001247233A1 (en) * | 2000-02-24 | 2001-09-03 | San Diego State University | Ppar gamma agonists for the treatment of liver inflammatory disorders |
WO2002072009A2 (en) | 2001-03-07 | 2002-09-19 | Maxia Pharmaceuticals, Inc. | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
JP2004523571A (en) | 2001-03-08 | 2004-08-05 | マキシア・ファーマシューティカルズ・インコーポレイテッド | RXR activating molecule |
US7071218B2 (en) | 2001-11-15 | 2006-07-04 | Incyte San Diego Incorporated | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases |
GB0128138D0 (en) * | 2001-11-23 | 2002-01-16 | King S College London | Pharmaceutical use |
US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
WO2008027069A1 (en) | 2006-08-21 | 2008-03-06 | Tearscience, Inc. | Method and apparatus for treating meibomian gland dysfunction employing fluid |
US9763827B2 (en) | 2013-04-30 | 2017-09-19 | Tear Film Innovations, Inc. | Systems and methods for the treatment of eye conditions |
EP3744391B1 (en) | 2013-04-30 | 2023-03-01 | Alcon Inc. | Systems for the treatment of eye conditions |
US10974063B2 (en) | 2016-06-30 | 2021-04-13 | Alcon Inc. | Light therapy for eyelash growth |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995035108A1 (en) * | 1994-06-22 | 1995-12-28 | The Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
WO1996024350A1 (en) * | 1995-02-10 | 1996-08-15 | Schering Aktiengesellschaft | Pharmaceutical preparations for tumour necrosis factor (tnf) inhibition |
WO1996034943A1 (en) * | 1995-05-04 | 1996-11-07 | City Of Hope | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states |
DE19540475A1 (en) * | 1995-10-20 | 1997-04-24 | Schering Ag | Chiral methylphenyloxazolidinones |
WO1997037688A2 (en) * | 1996-04-05 | 1997-10-16 | Takeda Chemical Industries, Ltd. | Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity |
WO1997045141A1 (en) * | 1996-05-31 | 1997-12-04 | Sankyo Company, Limited | Remedy for autoimmune diseases |
-
1998
- 1998-08-20 AU AU87479/98A patent/AU8747998A/en not_active Abandoned
- 1998-08-20 CA CA002300813A patent/CA2300813A1/en not_active Abandoned
- 1998-08-20 WO PCT/JP1998/003692 patent/WO1999009965A2/en not_active Application Discontinuation
- 1998-08-20 EP EP98938913A patent/EP1007038A2/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995035108A1 (en) * | 1994-06-22 | 1995-12-28 | The Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
WO1996024350A1 (en) * | 1995-02-10 | 1996-08-15 | Schering Aktiengesellschaft | Pharmaceutical preparations for tumour necrosis factor (tnf) inhibition |
WO1996034943A1 (en) * | 1995-05-04 | 1996-11-07 | City Of Hope | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states |
DE19540475A1 (en) * | 1995-10-20 | 1997-04-24 | Schering Ag | Chiral methylphenyloxazolidinones |
WO1997037688A2 (en) * | 1996-04-05 | 1997-10-16 | Takeda Chemical Industries, Ltd. | Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity |
WO1997045141A1 (en) * | 1996-05-31 | 1997-12-04 | Sankyo Company, Limited | Remedy for autoimmune diseases |
Non-Patent Citations (9)
Title |
---|
C. HOFMANN ET AL.: "Altered Gene Expression for Tumor Necrosis Factor-alpha and Its Receptors during Drug and Dietary Modulation of Insulin Resistance", ENDOCRINOLOGY, vol. 134, no. 1, January 1994 (1994-01-01), pages 264 - 270, XP002094464 * |
D.SZALKOWSKI ET AL.: "Antidiabetic Thiazolidinediones Block the Inhibitory Effect of Tumor Necrosis Factor-alpha on Differentiation, Insulin-Stimulated Glucose Uptake, and Gene Expression in 3T3-L1 Cells", ENDOCRINOLOGY, vol. 136, no. 4, April 1995 (1995-04-01), pages 1474 - 1481, XP002094465 * |
H.ODAKA ET AL.: "EFFECT OF PIOGLITAZONE ON SUCROSE-DETERIORATED DIABETIC STATES IN SPONTANEOUSLY DIABETIC GK RATS", DIALOG(R) FILE 5: BIOSIS PREVIEWS(R) ACCESSION NUMBER 07798952: J. JPN. DIABETES SOC., vol. 34, no. 6, 1991, pages 523 - 530, XP002094468 * |
M. SUZUKI ET AL.: "Nephropathy in genetically obese-diabetic Wistar fatty rats - Characterization and prevention", DIALOG(R) FILE 73: EMBASE, ACCESSION NUMBER 07010090: JPN. PHARMACOL. THER., vol. 25, no. 2, 1997, pages 43 - 51, XP002094469 * |
P. PERALDI ET AL.: "Thiazolidinediones Block Tumor Necrosis Factor-alpha.induced Inhibition of Insulin Signaling", J. CLIN.INVEST., vol. 100, no. 7, 1 October 1997 (1997-10-01), pages 1863 - 1869, XP002094470 * |
R.W.STEVENSON ET AL.: "The thiazolidinedione drug series", THE DIABETES ANNUAL, vol. 9, 1995, pages 175 - 191, XP002094463 * |
S.L. GROSSMAN ET AL.: "Mechanisms and clinical effects of thiazolidinediones", EXPERT OPIN. INVEST. DRUGS, vol. 6, no. 8, August 1997 (1997-08-01), pages 1025 - 1040, XP002094471 * |
S.S.SOLOMON ET AL.: "Pioglitazone and Metformin Reverse Insulin Resistance Induced by Tumor Necrosis Factor-Alpha in Liver Cells", HORMON. METAB. RES., vol. 29, no. 8, August 1997 (1997-08-01), pages 379 - 382, XP002094467 * |
T. YOSHIMOTO ET AL.: "Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats", AM.J.PHYSIOL., vol. 272, no. 6 Part 1, June 1997 (1997-06-01), pages E989 - E996, XP002094466 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7364736B2 (en) | 2001-06-26 | 2008-04-29 | Amgen Inc. | Antibodies to OPGL |
US9060843B2 (en) | 2005-07-18 | 2015-06-23 | Tearscience, Inc. | Method and apparatus for treating gland dysfunction employing heated medium |
US8950405B2 (en) | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
US9314369B2 (en) | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
Also Published As
Publication number | Publication date |
---|---|
CA2300813A1 (en) | 1999-03-04 |
AU8747998A (en) | 1999-03-16 |
WO1999009965A2 (en) | 1999-03-04 |
EP1007038A2 (en) | 2000-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999009965A3 (en) | Anti-inflammatory agent | |
AU1172999A (en) | Novel apoptosis inhibitors | |
CA2116387A1 (en) | Oxazolidinedione derivatives, their production and use | |
AU3461697A (en) | Heterocyclic compounds, their production and use | |
EP0513387A4 (en) | Active oxygen inhibitor | |
CA2054209A1 (en) | Antihyperlipidemic and antiatherosclerotic urea compounds | |
MY118904A (en) | 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents | |
CA2328780A1 (en) | Dihydropyrimidines | |
UA41290C2 (en) | HETEROARYLAMINES, PHARMACEUTICAL COMPOSITION, METHOD OF CHOLINESTERASE INHIBITION IN MAMMALS, METHOD OF MEMORY IMPROVEMENT | |
EA200100310A1 (en) | OXYGEN CONTAINING HETEROCYCLIC COMPOUNDS | |
WO2003035620A1 (en) | Bicyclic compound | |
EP0945764A3 (en) | Photoresist composition | |
CA2314564A1 (en) | Phosphonocephem derivatives, their production and use | |
CA2014490A1 (en) | Diaminoethylene compounds | |
CA2125549A1 (en) | Tetrazole derivatives, their production and use | |
WO2002000638A8 (en) | Substituted phthalides as anti-convulsive drugs | |
IE851734L (en) | Isoindolinyl-alkyl-piperazines | |
TW324009B (en) | Pyrazole condensation ring derivative, its production process and its use as androgen inhibitor | |
CA2247946A1 (en) | Anticachectic composition | |
CA2128093A1 (en) | 4-Aryl-3-(Heteroarylureido)-1,2-Dihydro-2-Oxoquinoline Derivatives as Antihypercholesterolemic and Antiatherosclerotic Agents | |
ES2120498T3 (en) | NEW TETRACYCLIC COMPOUND. | |
EP0516860A4 (en) | Chromone derivative and aldose reductase inhibitor containing the same as active ingredient | |
IE44180L (en) | Azaprostaglandins. | |
WO2003057215A1 (en) | Neurotrophic factor production/secretion accelerator | |
IE45092L (en) | Carbamic acid oxime-esters. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998938913 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09485640 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2300813 Country of ref document: CA Ref country code: CA Ref document number: 2300813 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1998938913 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998938913 Country of ref document: EP |